abrdn Life Sciences Investors (NYSE:HQL) Sees Significant Growth in Short Interest

Posted by Brian Himes on Sep 16th, 2026

abrdn Life Sciences Investors (NYSE:HQL – Get Free Report) was the recipient of a large increase in short interest in the month of August. As of August 31st, there was short interest totaling 100,177 shares, an increase of 70.9% from the August 15th total of 58,626 shares. Based on an average daily volume of 160,266 shares, the short-interest ratio is presently 0.6 days. Approximately 0.4% of the shares of the stock are short sold.

abrdn Life Sciences Investors Stock Down 0.7%

Shares of HQL traded down $0.13 during mid-day trading on Wednesday, reaching $19.26. 158,948 shares of the stock traded hands, compared to its average volume of 130,110. abrdn Life Sciences Investors has a 1 year low of $13.90 and a 1 year high of $22.67. The firm has a fifty day moving average price of $20.45 and a 200 day moving average price of $18.51.

abrdn Life Sciences Investors Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Monday, August 24th will be given a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a yield of 12.9%. The ex-dividend date is Monday, August 24th.

Institutional Trading of abrdn Life Sciences Investors

Several institutional investors and hedge funds have recently modified their holdings of HQL. Citadel Advisors LLC bought a new stake in shares of abrdn Life Sciences Investors during the 2nd quarter valued at about $287,000. Wedbush Securities Inc. raised its stake in abrdn Life Sciences Investors by 50.6% in the second quarter. Wedbush Securities Inc. now owns 15,960 shares of the company’s stock valued at $319,000 after purchasing an additional 5,360 shares in the last quarter. KPP Advisory Services LLC raised its stake in abrdn Life Sciences Investors by 2.7% in the second quarter. KPP Advisory Services LLC now owns 25,251 shares of the company’s stock valued at $505,000 after purchasing an additional 660 shares in the last quarter. 180 Wealth Advisors LLC lifted its position in abrdn Life Sciences Investors by 2.2% during the second quarter. 180 Wealth Advisors LLC now owns 152,829 shares of the company’s stock valued at $3,058,000 after purchasing an additional 3,271 shares during the last quarter. Finally, NewEdge Advisors LLC grew its stake in abrdn Life Sciences Investors by 17.6% in the 1st quarter. NewEdge Advisors LLC now owns 23,788 shares of the company’s stock worth $387,000 after buying an additional 3,562 shares in the last quarter. Hedge funds and other institutional investors own 32.21% of the company’s stock.

abrdn Life Sciences Investors Company Profile

(Get Free Report)

abrdn Life Sciences Investors (NYSE:HQL) is a non-diversified, closed-end investment company focused on the global life sciences sector. The fund seeks long-term capital appreciation by investing in companies involved in biotechnology, pharmaceuticals, medical devices, healthcare services and other related industries.

The fund may invest in both publicly traded and privately held companies across various stages of development, including businesses developing innovative therapies, diagnostic technologies and other healthcare products.